Representative Gilbert Ray Cisneros, Jr. (D-California) recently bought shares of Zoetis Inc. (NYSE:ZTS). In a filing disclosed on December 15th, the Representative disclosed that they had bought between $1,001 and $15,000 in Zoetis stock on November 18th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.
Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):
- Sold $1,001 – $15,000 in shares of Spotify Technology (NYSE:SPOT) on 11/26/2025.
- Sold $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOGL) on 11/26/2025.
- Purchased $1,001 – $15,000 in shares of First Watch Restaurant Group (NASDAQ:FWRG) on 11/26/2025.
- Purchased $1,001 – $15,000 in shares of TKO Group (NYSE:TKO) on 11/26/2025.
- Sold $1,001 – $15,000 in shares of RBC Bearings (NYSE:RBC) on 11/24/2025.
- Sold $1,001 – $15,000 in shares of Stifel Financial (NYSE:SF) on 11/24/2025.
- Purchased $1,001 – $15,000 in shares of Logan Energy (CVE:LGN) on 11/24/2025.
- Sold $1,001 – $15,000 in shares of Primoris Services (NASDAQ:PRIM) on 11/24/2025.
- Purchased $15,001 – $50,000 in shares of LandBridge (NYSE:LB) on 11/21/2025.
- Purchased $50,001 – $100,000 in shares of LandBridge (NYSE:LB) on 11/20/2025.
Zoetis Trading Down 0.3%
ZTS stock traded down $0.42 during mid-day trading on Friday, reaching $122.34. 11,250,821 shares of the stock traded hands, compared to its average volume of 3,464,274. The company has a debt-to-equity ratio of 1.31, a quick ratio of 2.28 and a current ratio of 3.64. The stock has a market capitalization of $53.91 billion, a PE ratio of 20.60, a PEG ratio of 2.66 and a beta of 0.97. Zoetis Inc. has a one year low of $115.25 and a one year high of $177.40. The business has a 50-day moving average price of $129.24 and a two-hundred day moving average price of $144.98.
Zoetis Increases Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 3rd. Stockholders of record on Tuesday, January 20th will be paid a $0.53 dividend. This represents a $2.12 annualized dividend and a dividend yield of 1.7%. The ex-dividend date of this dividend is Tuesday, January 20th. This is a positive change from Zoetis’s previous quarterly dividend of $0.50. Zoetis’s dividend payout ratio is 35.69%.
Wall Street Analyst Weigh In
ZTS has been the topic of several recent research reports. Morgan Stanley set a $160.00 price objective on shares of Zoetis in a report on Thursday. Bank of America cut Zoetis from a “buy” rating to a “neutral” rating and set a $135.00 target price for the company. in a report on Monday. KeyCorp initiated coverage on Zoetis in a research report on Thursday, November 20th. They issued a “sector weight” rating on the stock. Stifel Nicolaus dropped their price objective on Zoetis from $140.00 to $130.00 and set a “hold” rating for the company in a research note on Tuesday, November 18th. Finally, JPMorgan Chase & Co. dropped their price target on shares of Zoetis from $230.00 to $200.00 and set an “overweight” rating for the company in a research note on Wednesday, November 5th. Six equities research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company. According to MarketBeat.com, Zoetis presently has a consensus rating of “Hold” and an average price target of $160.18.
Read Our Latest Analysis on Zoetis
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently made changes to their positions in ZTS. Brighton Jones LLC raised its holdings in shares of Zoetis by 180.4% in the 4th quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock worth $754,000 after purchasing an additional 2,978 shares during the period. Raymond James Financial Inc. lifted its stake in shares of Zoetis by 1.8% during the first quarter. Raymond James Financial Inc. now owns 1,228,806 shares of the company’s stock worth $202,323,000 after purchasing an additional 21,840 shares in the last quarter. Steward Partners Investment Advisory LLC lifted its position in Zoetis by 2.6% during the 1st quarter. Steward Partners Investment Advisory LLC now owns 49,387 shares of the company’s stock worth $8,132,000 after acquiring an additional 1,236 shares in the last quarter. Freestone Capital Holdings LLC grew its position in Zoetis by 6.3% in the first quarter. Freestone Capital Holdings LLC now owns 36,940 shares of the company’s stock valued at $6,082,000 after acquiring an additional 2,185 shares in the last quarter. Finally, Summit Securities Group LLC acquired a new position in shares of Zoetis during the first quarter worth $64,000. Institutional investors and hedge funds own 92.80% of the company’s stock.
About Representative Cisneros
Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.
Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.
Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.
About Zoetis
Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.
Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.
See Also
- Five stocks we like better than Zoetis
- What is a Bond Market Holiday? How to Invest and Trade
- Nike Beats on Earnings But Struggles in China and Faces Tariffs
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Is the AI Boom a Bubble? These 2 Dividend Stocks Say No
- Consumer Discretionary Stocks Explained
- 4 High-Potential ETFs for 2026: Small Caps, Space Stocks, and More
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.
